
MindBio Therapeutics is a clinical-stage drug development company pursuing microdosing of psychedelic medicines to treat mental health conditions. It conducts clinical research and uses big data analytics and AI to enable precision medicine, with MB22001 in multiple Phase 2B trials for depression and anxiety in cancer patients. The company applies machine learning and AI-driven analysis to predict treatment responses and optimize regimens. MindBio aims to scale affordable psychedelic therapies for mental health.

MindBio Therapeutics is a clinical-stage drug development company pursuing microdosing of psychedelic medicines to treat mental health conditions. It conducts clinical research and uses big data analytics and AI to enable precision medicine, with MB22001 in multiple Phase 2B trials for depression and anxiety in cancer patients. The company applies machine learning and AI-driven analysis to predict treatment responses and optimize regimens. MindBio aims to scale affordable psychedelic therapies for mental health.